|
|
| Line 1: |
Line 1: |
| __NOTOC__
| | #REDIRECT [[Procainamide#Adult Indications and Dosage]] |
| {{Propafenone}}
| |
| {{CMG}}; {{AE}} {{SS}}
| |
| | |
| ==Dosage and Administration==
| |
| | |
| RYTHMOL SR can be taken with or without food. Do not crush or further divide the contents of the capsule.
| |
| | |
| The dose of RYTHMOL SR must be individually titrated on the basis of response and tolerance. Initiate therapy with RYTHMOL SR 225 mg given every 12 hours. Dosage may be increased at a minimum of 5-day intervals to 325 mg given every 12 hours. If additional therapeutic effect is needed, the dose of RYTHMOL SR may be increased to 425 mg given every 12 hours.
| |
| | |
| In patients with hepatic impairment or those with significant widening of the QRS complex or second-or third-degree AV block, consider reducing the dose.
| |
| | |
| The combination of CYP3A4 inhibition and either CYP2D6 deficiency or CYP2D6 inhibition with the simultaneous administration of propafenone may significantly increase the concentration of propafenone and thereby increase the risk of proarrhythmia and other adverse events. Therefore, avoid simultaneous use of RYTHMOL SR with both a CYP2D6 inhibitor and a CYP3A4 inhibitor [see Warnings and Precautions (5.4), Drug Interactions (7.1)].<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = RYTHMOL SR (PROPAFENONE HYDROCHLORIDE) CAPSULE, EXTENDED RELEASE [GLAXOSMITHKLINE LLC] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=8bb1bc4a-a019-49c8-af81-be899822428f | publisher = | date = | accessdate = 13 March 2014 }}</ref>
| |
| | |
| | |
| ==References==
| |
| {{Reflist}}
| |
| | |
| [[Category:Antiarrhythmic agents]]
| |
| [[Category:Ketones]]
| |
| [[Category:Phenol ethers]]
| |
| [[Category:Alcohols]]
| |
| [[Category:Amines]]
| |
| [[Category:Sodium channel blockers]]
| |
| [[Category:Cardiovascular Drugs]]
| |
| [[Category:Drugs]]
| |